See more : Lionheart III Corp (LIONU) Income Statement Analysis – Financial Results
Complete financial analysis of Annovis Bio, Inc. (ANVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Annovis Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fujian Acetron New Materials Co., Ltd. (300706.SZ) Income Statement Analysis – Financial Results
- The ONE Group Hospitality, Inc. (STKS) Income Statement Analysis – Financial Results
- Kansas City Southern (KSU) Income Statement Analysis – Financial Results
- AroCell AB (publ) (AROC.ST) Income Statement Analysis – Financial Results
- Yantai Jereh Oilfield Services Group Co., Ltd. (002353.SZ) Income Statement Analysis – Financial Results
Annovis Bio, Inc. (ANVS)
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 38.79M | 16.52M | 8.48M | 3.05M | 776.26K | 111.61K | 273.37K |
| General & Administrative | 6.24M | 9.00M | 6.06M | 3.59M | 829.37K | 602.33K | 409.06K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.24M | 9.00M | 6.06M | 3.59M | 829.37K | 602.33K | 409.06K |
| Other Expenses | 0.00 | 0.00 | -36.75K | -1.16M | -735.08K | 0.00 | 0.00 |
| Operating Expenses | 45.04M | 25.51M | 14.50M | 5.48M | 870.55K | 713.94K | 682.43K |
| Cost & Expenses | 45.04M | 25.51M | 14.50M | 5.48M | 870.55K | 713.94K | 682.43K |
| Interest Income | 667.90M | 182.71K | 13.34K | 47.23K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 47.23M | 0.00 | 66.00 | 84.00 |
| Depreciation & Amortization | 1.00 | 25.51M | 14.54M | 6.64M | 1.61M | 713.94K | 682.43K |
| EBITDA | -45.04M | 0.00 | 0.00 | 0.00 | 0.00 | 66.00 | 84.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.04M | -25.51M | -14.54M | -6.64M | -1.61M | -713.94K | -682.43K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -11.17M | 182.71K | 50.09K | 1.18M | 614.64K | 66.00 | 84.00 |
| Income Before Tax | -56.20M | -25.33M | -14.49M | -5.46M | -990.98K | -713.87K | -682.35K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -182.71K | -50.09K | -1.20M | -694.14K | -132.00 | -682.43K |
| Net Income | -56.20M | -25.15M | -14.44M | -4.26M | -296.84K | -713.87K | -682.35K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -6.23 | -3.08 | -1.89 | -0.67 | -0.07 | -0.16 | -0.16 |
| EPS Diluted | -6.23 | -3.08 | -1.89 | -0.67 | -0.07 | -0.16 | -0.16 |
| Weighted Avg Shares Out | 9.02M | 8.16M | 7.63M | 6.31M | 4.50M | 4.40M | 4.39M |
| Weighted Avg Shares Out (Dil) | 9.02M | 8.16M | 7.63M | 6.31M | 4.50M | 4.40M | 4.39M |
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer's Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer's Disease (AD) patients. The DSMB...
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer's Disease (AD) and Parkinson's Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer's Disease (CTAD)...
Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts
Annovis is expected to report data from Phase 3 and Phase 2/3 trials in Parkinson's and Alzheimer's disease, respectively. The efficacy of Annovis' lead compound, Buntanetap, is difficult to align with its proposed disease-modifying mechanism of action. Annovis has a...
Annovis (ANVS) AD Study to Continue as Planned, Shares Rise
Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in Alzheimer's Disease is sufficiently powered to continue as planned without any additional patients.
Top trending biotech stocks: ANVS, MTNB, AVTX, TPST
Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's acquisition of Seagen, Eli Lilly's...
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer's Study
Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer's Disease (AD) is sufficiently powered to continue as planned without any additional patients Pre-specified, blinded interim analysis for sample size re-estimation indicates that...
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer's Disease (AD) and Parkinson's Disease (PD) announced second quarter financial results for the period ended June 30, 2023,...
3 Biotech Stocks to Buy Before Drug Trials End
Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to receive FDA approval.
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer's Disease (AD) and Parkinson's Disease (PD), presented three posters at the Alzheimer's Association International Conference (AAIC) 2023 annual...
Annovis Bio Announces the Filing of a Groundbreaking Patent
BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), a clinical stage drug platform company developing novel and transformative therapies for neurodegenerative diseases, announces the creation of a novel crystalline form of buntanetap (ANVS402), and the filing of a new composition of...
Source: https://incomestatements.info
Category: Stock Reports